Jiazhong Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiazhong Sun has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Yancheng Xu
Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
8 shared publications Shiqi Sun
Department of Laboratory Medicine, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University
7 shared publicationsQi Huang
Department of Endocrinology, Zhongnan Hospital of Wuhan University
6 shared publicationsYanlei Sun
Wuhan University
5 shared publicationsHongyun Lu
3 shared publicationsShengming Zhou
Department of Endocrinology, The First People’s Hospital of Xiaogan, Xiaogan, China
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1906731
Immune checkpoint inhibitor–related pancreatitis with fulminant type 1 diabetes mellitus: a case report
Background: Immune checkpoint inhibitors (ICIs) are widely used in tumor therapy, and the immune-related adverse events (irAEs) they induce can involve multiple organs. As an organ with both endocrine and exocrine functions, pancreatic involvement may manifest as acute pancreatitis, new-onset diabetes mellitus, or even a combination of both. Among these, ICI-induced acute pancreatitis concurrent with fulminant type 1 diabetes mellitus (FT1DM) is extremely rare but highly critical and easily missed in clinical practice. Case presentation: A 59-year-old male patient with squamous cell carcinoma of the left base of the tongue received toripalimab combined with chemotherapy. On day 7 after treatment, he presented with nausea, vomiting, and altered mental status. Emergency examination revealed hyperglycemia (17.4 mmol/L), severe diabetic ketoacidosis (blood ketones 9.52 mmol/L, pH 7.28), and significantly elevated serum amylase (370 U/L). Abdominal CT showed swelling of the body and tail of the pancreas with surrounding exudation, consistent with acute pancreatitis. His glycated hemoglobin (HbA1c) was normal (5.4%), pancreatic autoantibodies were negative, and islet function was completely lost. He was diagnosed with toripalimab-associated acute pancreatitis (Grade 3) concurrent with FT1DM. ICIs were permanently discontinued immediately. The patient was treated with fasting, fluid replacement, somatostatin to inhibit pancreatic enzyme secretion, and intensive insulin pump therapy for glycemic control. Glucocorticoids were not administered. After 11 days of comprehensive treatment, his symptoms resolved, and he was discharged upon normalization of pancreatic enzymes and blood glucose levels. Conclusion: PD-1 inhibitors can simultaneously impair both the endocrine and exocrine functions of the pancreas, leading to the coexistence of acute pancreatitis and FT1DM. Clinicians must maintain a high index of suspicion for this dual injury. For patients receiving ICI therapy, emergency evaluation of pancreatic function is warranted once gastrointestinal symptoms or unexplained hyperglycemia/ketosis occur. Early drug withdrawal and individualized management centered on supportive care can effectively prevent life-threatening complications. Notably, this case represents the first report of such dual pancreatic injury in a patient with locally advanced tongue base squamous cell carcinoma receiving first-cycle toripalimab combined with paclitaxel plus cisplatin chemoimmunotherapy, with distinct atypical clinical manifestations and a faster steroid-free recovery trajectory compared with the single previously published toripalimab-associated case.
- 15 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1906731
Open AccessImmune checkpoint inhibitor–related pancreatitis with fulminant type 1 diabetes mellitus: a case report
Background: Immune checkpoint inhibitors (ICIs) are widely used in tumor therapy, and the immune-related adverse events (irAEs) they induce can involve multiple organs. As an organ with both endocrine and exocrine functions, pancreatic involvement may manifest as acute pancreatitis, new-onset diabetes mellitus, or even a combination of both. Among these, ICI-induced acute pancreatitis concurrent with fulminant type 1 diabetes mellitus (FT1DM) is extremely rare but highly critical and easily missed in clinical practice. Case presentation: A 59-year-old male patient with squamous cell carcinoma of the left base of the tongue received toripalimab combined with chemotherapy. On day 7 after treatment, he presented with nausea, vomiting, and altered mental status. Emergency examination revealed hyperglycemia (17.4 mmol/L), severe diabetic ketoacidosis (blood ketones 9.52 mmol/L, pH 7.28), and significantly elevated serum amylase (370 U/L). Abdominal CT showed swelling of the body and tail of the pancreas with surrounding exudation, consistent with acute pancreatitis. His glycated hemoglobin (HbA1c) was normal (5.4%), pancreatic autoantibodies were negative, and islet function was completely lost. He was diagnosed with toripalimab-associated acute pancreatitis (Grade 3) concurrent with FT1DM. ICIs were permanently discontinued immediately. The patient was treated with fasting, fluid replacement, somatostatin to inhibit pancreatic enzyme secretion, and intensive insulin pump therapy for glycemic control. Glucocorticoids were not administered. After 11 days of comprehensive treatment, his symptoms resolved, and he was discharged upon normalization of pancreatic enzymes and blood glucose levels. Conclusion: PD-1 inhibitors can simultaneously impair both the endocrine and exocrine functions of the pancreas, leading to the coexistence of acute pancreatitis and FT1DM. Clinicians must maintain a high index of suspicion for this dual injury. For patients receiving ICI therapy, emergency evaluation of pancreatic function is warranted once gastrointestinal symptoms or unexplained hyperglycemia/ketosis occur. Early drug withdrawal and individualized management centered on supportive care can effectively prevent life-threatening complications. Notably, this case represents the first report of such dual pancreatic injury in a patient with locally advanced tongue base squamous cell carcinoma receiving first-cycle toripalimab combined with paclitaxel plus cisplatin chemoimmunotherapy, with distinct atypical clinical manifestations and a faster steroid-free recovery trajectory compared with the single previously published toripalimab-associated case.
- Open Access
- 18 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Pueraria lobata extract mitigates diabetic nephropathy via NLRP3 inflammasome and Caspase-1 regulation
To elucidate novel mechanisms underlying puerariae lobatae extract (EPL) therapeutic efficacy against diabetic nephropathy, with a focus on NLRP3 inflammasome regulation in streptozotocin (STZ)-induced renal pathology. 60 Wistar rats were randomly divided into five groups: a normal control (NC) group, a model (Model) group, an EPL (EPL) group, an NLRP3 activator group (NLRP3), and an NLRP3 activator + EPL group (NLRP3 + EPL), with 12 rats in each group. Diabetic kidney injury was induced in rats by intraperitoneal injection of streptozotocin (STZ). ELISA was used to measure serum creatinine (Scr), blood urea nitrogen (BUN), serum uric acid (SUA), 24-hour urinary albumin (UAlb), malondialdehyde (MDA) in renal tissue, superoxide dismutase (SOD), interleukin-1β (IL-1β), and IL-18. Histopathological changes in renal tissue were observed by hematoxylin and eosin (HE) staining. The content of reactive oxygen species (ROS) in renal tissue was detected by chemiluminescence. qRT-PCR was employed to detect the mRNA expression of NLRP3 and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) in renal tissue. Western blot was used to assess the protein expression of NLRP3, ASC, and cysteine aspartic acid protease 1(caspase-1) in renal tissue. EPL intervention demonstrated: Significant body weight recovery (143.62 ± 6.18 g vs. DN 110.53 ± 5.69 g, P < 0.05); Renal functional restoration: 34.8% reduction in Scr (15.96 ± 2.31 vs. 35.19 ± 5.27 µmol/L), 49.7% decrease in BUN (9.16 ± 0.35 vs. 18.21 ± 0.85 mmol/L); Oxidative homeostasis improvement: 35.5% MDA reduction (2.38 ± 0.31 vs. 3.69 ± 0.42 nmol/mg), 56.8% ROS suppression (25.52 × 10⁴ vs. 59.08 × 10⁴/mg); Inflammasome downregulation: 62.3% decrease in NLRP3 mRNA, 58.1% ASC protein reduction, and 47.6% Caspase-1 activation inhibition. This study establishes that EPL ameliorates diabetic renal injury by suppressing NLRP3 inflammasome activation and Caspase-1-mediated signaling, providing mechanistic validation for EPL’s therapeutic potential in metabolic nephropathy management.
- 18 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPueraria lobata extract mitigates diabetic nephropathy via NLRP3 inflammasome and Caspase-1 regulation
To elucidate novel mechanisms underlying puerariae lobatae extract (EPL) therapeutic efficacy against diabetic nephropathy, with a focus on NLRP3 inflammasome regulation in streptozotocin (STZ)-induced renal pathology. 60 Wistar rats were randomly divided into five groups: a normal control (NC) group, a model (Model) group, an EPL (EPL) group, an NLRP3 activator group (NLRP3), and an NLRP3 activator + EPL group (NLRP3 + EPL), with 12 rats in each group. Diabetic kidney injury was induced in rats by intraperitoneal injection of streptozotocin (STZ). ELISA was used to measure serum creatinine (Scr), blood urea nitrogen (BUN), serum uric acid (SUA), 24-hour urinary albumin (UAlb), malondialdehyde (MDA) in renal tissue, superoxide dismutase (SOD), interleukin-1β (IL-1β), and IL-18. Histopathological changes in renal tissue were observed by hematoxylin and eosin (HE) staining. The content of reactive oxygen species (ROS) in renal tissue was detected by chemiluminescence. qRT-PCR was employed to detect the mRNA expression of NLRP3 and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) in renal tissue. Western blot was used to assess the protein expression of NLRP3, ASC, and cysteine aspartic acid protease 1(caspase-1) in renal tissue. EPL intervention demonstrated: Significant body weight recovery (143.62 ± 6.18 g vs. DN 110.53 ± 5.69 g, P < 0.05); Renal functional restoration: 34.8% reduction in Scr (15.96 ± 2.31 vs. 35.19 ± 5.27 µmol/L), 49.7% decrease in BUN (9.16 ± 0.35 vs. 18.21 ± 0.85 mmol/L); Oxidative homeostasis improvement: 35.5% MDA reduction (2.38 ± 0.31 vs. 3.69 ± 0.42 nmol/mg), 56.8% ROS suppression (25.52 × 10⁴ vs. 59.08 × 10⁴/mg); Inflammasome downregulation: 62.3% decrease in NLRP3 mRNA, 58.1% ASC protein reduction, and 47.6% Caspase-1 activation inhibition. This study establishes that EPL ameliorates diabetic renal injury by suppressing NLRP3 inflammasome activation and Caspase-1-mediated signaling, providing mechanistic validation for EPL’s therapeutic potential in metabolic nephropathy management.
- Open Access
- 7 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
High glucose fluctuation levels modulate monocyte cytokine expression via oxidative stress mechanism
This study investigated the impact of glycemic variability on cytokine expression (MCP-1, IL-6, TNF-α) and oxidative stress in monocytes, and explored the protective effect of the antioxidant α-lipoic acid (ALA). Human THP-1 monocytes were cultured under four conditions: stable normoglycemia (5 mmol/L), persistent hyperglycemia (20 mmol/L), low-amplitude glucose fluctuation (alternating between 5 and 20 mmol/L), and high-amplitude fluctuation (alternating between 5 and 30 mmol/L). The effects of ALA supplementation were assessed in parallel. Compared to the normoglycemic control, intracellular oxidative stress was significantly elevated in all hyperglycemic groups (p < 0.05), with the highest levels observed in the high-amplitude fluctuation group (p < 0.05 vs. low-amplitude fluctuation). Both sustained and fluctuating hyperglycemia upregulated the mRNA and protein expression of MCP-1, IL-6, and TNF-α (p < 0.05 vs. normal control). ALA treatment markedly suppressed this cytokine overexpression (p < 0.05). Furthermore, ALA significantly attenuated oxidative stress (p < 0.05) and restored antioxidant enzyme activity across all hyperglycemic groups. In this monocyte model, high-amplitude glucose fluctuations induced greater oxidative stress and inflammatory cytokine dysregulation than sustained hyperglycemia, with the severity correlating with the fluctuation magnitude. The antioxidant α-lipoic acid attenuated these effects, suggesting a potential role for oxidative stress in this process. Further research is needed to elucidate the precise causal mechanisms linking glucose fluctuations to monocyte dysfunction.
- 7 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessHigh glucose fluctuation levels modulate monocyte cytokine expression via oxidative stress mechanism
This study investigated the impact of glycemic variability on cytokine expression (MCP-1, IL-6, TNF-α) and oxidative stress in monocytes, and explored the protective effect of the antioxidant α-lipoic acid (ALA). Human THP-1 monocytes were cultured under four conditions: stable normoglycemia (5 mmol/L), persistent hyperglycemia (20 mmol/L), low-amplitude glucose fluctuation (alternating between 5 and 20 mmol/L), and high-amplitude fluctuation (alternating between 5 and 30 mmol/L). The effects of ALA supplementation were assessed in parallel. Compared to the normoglycemic control, intracellular oxidative stress was significantly elevated in all hyperglycemic groups (p < 0.05), with the highest levels observed in the high-amplitude fluctuation group (p < 0.05 vs. low-amplitude fluctuation). Both sustained and fluctuating hyperglycemia upregulated the mRNA and protein expression of MCP-1, IL-6, and TNF-α (p < 0.05 vs. normal control). ALA treatment markedly suppressed this cytokine overexpression (p < 0.05). Furthermore, ALA significantly attenuated oxidative stress (p < 0.05) and restored antioxidant enzyme activity across all hyperglycemic groups. In this monocyte model, high-amplitude glucose fluctuations induced greater oxidative stress and inflammatory cytokine dysregulation than sustained hyperglycemia, with the severity correlating with the fluctuation magnitude. The antioxidant α-lipoic acid attenuated these effects, suggesting a potential role for oxidative stress in this process. Further research is needed to elucidate the precise causal mechanisms linking glucose fluctuations to monocyte dysfunction.
- Open Access
- 12 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1790631
Case report: Thymoma-associated GAD65 autoimmunity: a unifying mechanism for multi-organ injury involving nervous, endocrine, and renal systems
Thymomas are well-established disruptors of central immune tolerance, yet their capacity to drive systemic autoimmunity via a single autoantigen remains incompletely characterized. We report a 59-year-old male who, following resection of a Masaoka stage IIb type B2 thymoma, developed sequential neurological, endocrine, and renal manifestations over 18 months. Clinical evaluation confirmed stiff-person syndrome (SPS) with axial muscle hypermetabolism on PET-CT, latent autoimmune diabetes (HbA1c 11%), subclinical hypothyroidism (TSH 15.28 μIU/mL), and distal renal tubular acidosis (dRTA) evidenced by severe hypokalemia (K + 2.4 mmol/L) and inappropriately alkaline urine (pH 7.5). All three syndromes were associated with persistently high-titer glutamic acid decarboxylase 65 (GAD65) autoantibodies (>500 nmol/L in serum). Epitope mapping identified molecular mimicry between the GAD65 peptide ² 60 PEVKEK² 65 and homologous sequences in renal H + -ATPase and thyroid peroxidase, providing a mechanistic basis for multi-organ cross-reactivity. Treatment with intravenous immunoglobulin (IVIG) led to a 53.6% reduction in serum and an 80% decline in cerebrospinal fluid GAD65 antibody levels, paralleling clinical improvement. This case illustrates how thymoma-induced loss of tolerance to GAD65 can trigger widespread autoimmune injury through conformational epitope spreading, positioning GAD65 as a paraneoplastic pan-autoantigen. High-titer GAD65 antibodies may serve as a biomarker for systemic involvement, supporting early multidisciplinary surveillance in thymoma patients.
- 12 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1790631
Open AccessCase report: Thymoma-associated GAD65 autoimmunity: a unifying mechanism for multi-organ injury involving nervous, endocrine, and renal systems
Thymomas are well-established disruptors of central immune tolerance, yet their capacity to drive systemic autoimmunity via a single autoantigen remains incompletely characterized. We report a 59-year-old male who, following resection of a Masaoka stage IIb type B2 thymoma, developed sequential neurological, endocrine, and renal manifestations over 18 months. Clinical evaluation confirmed stiff-person syndrome (SPS) with axial muscle hypermetabolism on PET-CT, latent autoimmune diabetes (HbA1c 11%), subclinical hypothyroidism (TSH 15.28 μIU/mL), and distal renal tubular acidosis (dRTA) evidenced by severe hypokalemia (K + 2.4 mmol/L) and inappropriately alkaline urine (pH 7.5). All three syndromes were associated with persistently high-titer glutamic acid decarboxylase 65 (GAD65) autoantibodies (>500 nmol/L in serum). Epitope mapping identified molecular mimicry between the GAD65 peptide ² 60 PEVKEK² 65 and homologous sequences in renal H + -ATPase and thyroid peroxidase, providing a mechanistic basis for multi-organ cross-reactivity. Treatment with intravenous immunoglobulin (IVIG) led to a 53.6% reduction in serum and an 80% decline in cerebrospinal fluid GAD65 antibody levels, paralleling clinical improvement. This case illustrates how thymoma-induced loss of tolerance to GAD65 can trigger widespread autoimmune injury through conformational epitope spreading, positioning GAD65 as a paraneoplastic pan-autoantigen. High-titer GAD65 antibodies may serve as a biomarker for systemic involvement, supporting early multidisciplinary surveillance in thymoma patients.
- Open Access
- 15 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (12)
Methylation status of leptin gene promoter in relatively lean Chinese adults with prediabetes and type 2 diabetes mellitus
BACKGROUND Epigenetic regulation of leptin (LEP) plays a critical role in metabolic disorders, yet its promoter methylation patterns in lean diabetic populations remain poorly characterized. Emerging evidence suggests DNA methylation may precede clinical hyperglycemia, offering potential for early risk stratification. While obesity-associated LEP methylation is well-studied, lean Asian populations who exhibit high diabetes prevalence despite lower adiposity, represent an underexplored cohort. This study hypothesizes that LEP promoter methylation in peripheral leukocytes decreases progressively from normoglycemia to prediabetes and type 2 diabetes mellitus (T2DM), correlating inversely with serum LEP levels in lean Chinese adults [body mass index (BMI) < 24 kg/m2]. AIM To investigate LEP promoter methylation status and its association with serum LEP levels across glycemic states in lean Chinese adults. METHODS We enrolled 392 participants including 120 normoglycemic controls, 94 prediabetes [44 impaired fasting glucose (IFG)/50 impaired glucose tolerance (IGT)], 178 T2DM aged 40-60 years with BMI < 24 kg/m2. Genomic DNA from peripheral leukocytes underwent bisulfite conversion followed by methylation-specific PCR to assess CpG methylation in the LEP promoter. Serum LEP was quantified via enzyme-linked immunosorbent assay, with other parameters measured through standard assays. Statistical analyses included analysis of variance, χ ² tests, and Pearson correlation (Bonferroni-corrected P value). RESULTS Methylation frequencies declined progressively: 59.2% (controls) reduced to 43.6% (prediabetes; IFG: 38.6%, IGT: 48%) reduced to 31.5% (T2DM) (all P < 0.05 vs controls; T2DM vs IGT: P = 0.030). Serum LEP levels increased significantly in T2DM (16.94 ± 4.19 μg/L) vs controls (11.33 ± 3.10 μg/L; P = 0.002), with intermediate values in prediabetes (IFG: 13.79 ± 3.32 μg/L; IGT: 12.62 ± 4.81 μg/L). A near-perfect inverse correlation between methylation and LEP levels was observed (r = -0.95, 95%CI: -0.97 to -0.92, P < 0.001), persisting after adjusting for age and BMI (β = -0.91, P < 0.001). CONCLUSION LEP promoter hypomethylation parallels worsening glycemic status in lean Chinese adults, suggesting its potential as a blood-based epigenetic biomarker for diabetes progression, pending validation in longitudinal cohorts.
- 15 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (12)
Open AccessMethylation status of leptin gene promoter in relatively lean Chinese adults with prediabetes and type 2 diabetes mellitus
BACKGROUND Epigenetic regulation of leptin (LEP) plays a critical role in metabolic disorders, yet its promoter methylation patterns in lean diabetic populations remain poorly characterized. Emerging evidence suggests DNA methylation may precede clinical hyperglycemia, offering potential for early risk stratification. While obesity-associated LEP methylation is well-studied, lean Asian populations who exhibit high diabetes prevalence despite lower adiposity, represent an underexplored cohort. This study hypothesizes that LEP promoter methylation in peripheral leukocytes decreases progressively from normoglycemia to prediabetes and type 2 diabetes mellitus (T2DM), correlating inversely with serum LEP levels in lean Chinese adults [body mass index (BMI) < 24 kg/m2]. AIM To investigate LEP promoter methylation status and its association with serum LEP levels across glycemic states in lean Chinese adults. METHODS We enrolled 392 participants including 120 normoglycemic controls, 94 prediabetes [44 impaired fasting glucose (IFG)/50 impaired glucose tolerance (IGT)], 178 T2DM aged 40-60 years with BMI < 24 kg/m2. Genomic DNA from peripheral leukocytes underwent bisulfite conversion followed by methylation-specific PCR to assess CpG methylation in the LEP promoter. Serum LEP was quantified via enzyme-linked immunosorbent assay, with other parameters measured through standard assays. Statistical analyses included analysis of variance, χ ² tests, and Pearson correlation (Bonferroni-corrected P value). RESULTS Methylation frequencies declined progressively: 59.2% (controls) reduced to 43.6% (prediabetes; IFG: 38.6%, IGT: 48%) reduced to 31.5% (T2DM) (all P < 0.05 vs controls; T2DM vs IGT: P = 0.030). Serum LEP levels increased significantly in T2DM (16.94 ± 4.19 μg/L) vs controls (11.33 ± 3.10 μg/L; P = 0.002), with intermediate values in prediabetes (IFG: 13.79 ± 3.32 μg/L; IGT: 12.62 ± 4.81 μg/L). A near-perfect inverse correlation between methylation and LEP levels was observed (r = -0.95, 95%CI: -0.97 to -0.92, P < 0.001), persisting after adjusting for age and BMI (β = -0.91, P < 0.001). CONCLUSION LEP promoter hypomethylation parallels worsening glycemic status in lean Chinese adults, suggesting its potential as a blood-based epigenetic biomarker for diabetes progression, pending validation in longitudinal cohorts.
- Open Access
- 29 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (35) , e44107
Pelvic lipomatosis—A silent intruder in the pelvis: Clinical insights from a case report and literature analysis
Rationale: This study aims to highlight the diagnostic challenges and multidisciplinary management of pelvic lipomatosis (PL), emphasizing imaging’s pivotal role and the need for early intervention to mitigate long-term morbidity. With fewer than 200 reported cases, PL remains underrecognized; this case underscores its potential to mimic common gastrointestinal/urinary disorders, advocating for heightened clinical suspicion. Patient concerns: A 42-year-old male presented with a 2-day history of colicky abdominal pain under the xiphoid process, ac companied by nausea, vomiting, and watery stools. Initial external hospital evaluations suggested small bowel obstruction and mesenteric lymphadenitis. Past medical history included abnormal blood glucose levels. Physical examination revealed right upper abdominal tenderness and mild distension. Diagnoses: Imaging studies were pivotal. Emergency abdominal–pelvic computed tomography showed diffuse low-density fat accumulation compressing the bladder and rectum (“pelvic lucency sign”), thickened bladder walls, and enlarged mesenteric lymph nodes. Subsequent magnetic resonance imaging confirmed symmetrical pelvic fat deposition with bladder deformation and elevated bladder base. Laboratory tests revealed mildly elevated bilirubin, C-reactive protein, and triglycerides, but no significant urinary or metabolic abnormalities. Final diagnosis confirmed PL with concurrent prostatitis and pelvic inflammatory changes. Interventions: The patient received conservative management, including acid suppression, gastric protection, nutritional support, and symptomatic relief. Surgical intervention was deferred due to symptom improvement. Post-discharge recommendations included dietary control, weight management, and regular follow-up for monitoring disease progression. Outcomes: Clinical resolution: symptoms resolved with conservative management including acid suppression and nutritional support, with the patient discharged in stable condition. Imaging correlation: magnetic resonance imaging confirmed symmetrical pelvic fat deposition with bladder deformation, while computed tomography demonstrated the characteristic “pelvic lucency sign.” Long-term planning: regular monitoring was instituted for potential urinary obstruction and malignancy risk given established associations with chronic cystitis. Lessons: PL poses diagnostic challenges due to nonspecific symptoms and often mimics gastrointestinal or urinary disorders. Imaging remains critical for accurate diagnosis. While conservative management suffices in mild cases, surgical options should be considered for severe organ compression. This case underscores the importance of early recognition, multidisciplinary evaluation, and tailored management to mitigate long-term morbidity.
- 29 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (35) , e44107
Open AccessPelvic lipomatosis—A silent intruder in the pelvis: Clinical insights from a case report and literature analysis
Rationale: This study aims to highlight the diagnostic challenges and multidisciplinary management of pelvic lipomatosis (PL), emphasizing imaging’s pivotal role and the need for early intervention to mitigate long-term morbidity. With fewer than 200 reported cases, PL remains underrecognized; this case underscores its potential to mimic common gastrointestinal/urinary disorders, advocating for heightened clinical suspicion. Patient concerns: A 42-year-old male presented with a 2-day history of colicky abdominal pain under the xiphoid process, ac companied by nausea, vomiting, and watery stools. Initial external hospital evaluations suggested small bowel obstruction and mesenteric lymphadenitis. Past medical history included abnormal blood glucose levels. Physical examination revealed right upper abdominal tenderness and mild distension. Diagnoses: Imaging studies were pivotal. Emergency abdominal–pelvic computed tomography showed diffuse low-density fat accumulation compressing the bladder and rectum (“pelvic lucency sign”), thickened bladder walls, and enlarged mesenteric lymph nodes. Subsequent magnetic resonance imaging confirmed symmetrical pelvic fat deposition with bladder deformation and elevated bladder base. Laboratory tests revealed mildly elevated bilirubin, C-reactive protein, and triglycerides, but no significant urinary or metabolic abnormalities. Final diagnosis confirmed PL with concurrent prostatitis and pelvic inflammatory changes. Interventions: The patient received conservative management, including acid suppression, gastric protection, nutritional support, and symptomatic relief. Surgical intervention was deferred due to symptom improvement. Post-discharge recommendations included dietary control, weight management, and regular follow-up for monitoring disease progression. Outcomes: Clinical resolution: symptoms resolved with conservative management including acid suppression and nutritional support, with the patient discharged in stable condition. Imaging correlation: magnetic resonance imaging confirmed symmetrical pelvic fat deposition with bladder deformation, while computed tomography demonstrated the characteristic “pelvic lucency sign.” Long-term planning: regular monitoring was instituted for potential urinary obstruction and malignancy risk given established associations with chronic cystitis. Lessons: PL poses diagnostic challenges due to nonspecific symptoms and often mimics gastrointestinal or urinary disorders. Imaging remains critical for accurate diagnosis. While conservative management suffices in mild cases, surgical options should be considered for severe organ compression. This case underscores the importance of early recognition, multidisciplinary evaluation, and tailored management to mitigate long-term morbidity.
- Open Access
- 22 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
The unique relationship between body mass index and metabolic syndrome in AIDS patients
Metabolic syndrome (MS) poses substantial health risks for people living with HIV/AIDS (PLWHA). While body mass index (BMI) is a well-established predictor of MS in the general population, its association with MS in PLWHA remains poorly characterized, particularly in China. This study investigates the relationship between BMI and MS in Chinese AIDS patients, with emphasis on population-specific metabolic risk patterns and threshold deviations from general population benchmarks. We enrolled 482 hospitalized AIDS patients stratified by BMI categories: underweight (< 18.5 kg/m², n = 92), normal weight (18.5–23.9 kg/m², n = 311), and overweight/obese (≥ 24 kg/m², n = 79). MS diagnosis followed Chinese Diabetes Society (CDS) criteria. Comparative analyses of blood pressure, fasting glucose, and lipid profiles were conducted across groups. Statistical approaches included Spearman correlation for BMI-MS associations, multivariate logistic regression (adjusted for age, sex, and metabolic parameters), and ROC curve analysis to determine BMI thresholds predictive of MS. The overall MS prevalence was 8.92% (43/482), with striking disparities between groups: overweight/obese patients demonstrated 3.5-fold higher MS prevalence than normal-weight counterparts (24.1% vs. 6.8%, P < 0.001). Metabolic derangements were disproportionately elevated in the overweight/obese group, including hypertension (31.6% vs. 12.2%) and hypertriglyceridemia (44.3% vs. 21.5%, both P < 0.05). BMI showed strong positive correlations with MS diagnosis (r = 0.42, P < 0.001) and MS component burden (r = 0.38, P < 0.001). Multivariate analysis identified BMI as an independent MS predictor (adjusted OR = 1.15 per unit increase, 95% CI:1.06–1.25, P < 0.05). ROC analysis revealed a clinically relevant BMI cut-off of 20 kg/m² for MS prediction (AUC = 0.79), substantially lower than general population thresholds. This study identifies an accentuated BMI-MS relationship in Chinese PLWHA, with metabolic complications emerging at atypically low BMI values. The proposed BMI threshold of 20 kg/m² for MS risk stratification—25% below standard obesity criteria. Urgent adoption of HIV-specific metabolic screening is needed, prioritizing early BMI-guided interventions to reduce cardiovascular risks, even in non-obese individuals.
- 22 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessThe unique relationship between body mass index and metabolic syndrome in AIDS patients
Metabolic syndrome (MS) poses substantial health risks for people living with HIV/AIDS (PLWHA). While body mass index (BMI) is a well-established predictor of MS in the general population, its association with MS in PLWHA remains poorly characterized, particularly in China. This study investigates the relationship between BMI and MS in Chinese AIDS patients, with emphasis on population-specific metabolic risk patterns and threshold deviations from general population benchmarks. We enrolled 482 hospitalized AIDS patients stratified by BMI categories: underweight (< 18.5 kg/m², n = 92), normal weight (18.5–23.9 kg/m², n = 311), and overweight/obese (≥ 24 kg/m², n = 79). MS diagnosis followed Chinese Diabetes Society (CDS) criteria. Comparative analyses of blood pressure, fasting glucose, and lipid profiles were conducted across groups. Statistical approaches included Spearman correlation for BMI-MS associations, multivariate logistic regression (adjusted for age, sex, and metabolic parameters), and ROC curve analysis to determine BMI thresholds predictive of MS. The overall MS prevalence was 8.92% (43/482), with striking disparities between groups: overweight/obese patients demonstrated 3.5-fold higher MS prevalence than normal-weight counterparts (24.1% vs. 6.8%, P < 0.001). Metabolic derangements were disproportionately elevated in the overweight/obese group, including hypertension (31.6% vs. 12.2%) and hypertriglyceridemia (44.3% vs. 21.5%, both P < 0.05). BMI showed strong positive correlations with MS diagnosis (r = 0.42, P < 0.001) and MS component burden (r = 0.38, P < 0.001). Multivariate analysis identified BMI as an independent MS predictor (adjusted OR = 1.15 per unit increase, 95% CI:1.06–1.25, P < 0.05). ROC analysis revealed a clinically relevant BMI cut-off of 20 kg/m² for MS prediction (AUC = 0.79), substantially lower than general population thresholds. This study identifies an accentuated BMI-MS relationship in Chinese PLWHA, with metabolic complications emerging at atypically low BMI values. The proposed BMI threshold of 20 kg/m² for MS risk stratification—25% below standard obesity criteria. Urgent adoption of HIV-specific metabolic screening is needed, prioritizing early BMI-guided interventions to reduce cardiovascular risks, even in non-obese individuals.
- Open Access
- 1 April 2025
- Published by Springer Nature in Research Square
The Unique Relationship between Body Mass Index and Metabolic Syndrome in AIDS Patients
Introduction Metabolic syndrome (MS) poses substantial health risks for people living with HIV/AIDS (PLWHA). While body mass index (BMI) is a well-established predictor of MS in the general population, its association with MS in PLWHA remains poorly characterized, particularly in China. This study investigates the relationship between BMI and MS in Chinese AIDS patients, with emphasis on population-specific metabolic risk patterns andthreshold deviations from general population benchmarks. Methods We enrolled 482 hospitalized AIDS patients stratified by BMI categories: underweight (<18.5 kg/m², n=92), normal weight (18.5–23.9 kg/m², n=311), and overweight/obese (≥24 kg/m², n=79). MS diagnosis followed Chinese Diabetes Society (CDS) criteria. Comparative analyses of blood pressure, fasting glucose, and lipid profiles were conducted across groups. Statistical approaches included Spearman correlation for BMI-MS associations, multivariate logistic regression (adjusted for age, sex, and metabolic parameters), and ROC curve analysis to determine BMI thresholds predictive of MS. Results The overall MS prevalence was 8.92% (43/482), with striking disparities between groups: overweight/obese patients demonstrated 3.5-fold higher MS prevalence than normal-weight counterparts (24.1% vs. 6.8%, P<0.001). Metabolic derangements were disproportionately elevated in the overweight/obese group, including hypertension (31.6% vs. 12.2%) and hypertriglyceridemia (44.3% vs. 21.5%, both P<0.05). BMI showed strong positive correlations with MS diagnosis (r=0.42, P<0.001) and MS component burden (r=0.38, P<0.001). Multivariate analysis identified BMI as an independent MS predictor (adjusted OR=1.15 per unit increase, 95% CI:1.06–1.25, P<0.05). ROC analysis revealed a clinically relevant BMI cut-off of 20 kg/m² for MS prediction (AUC=0.79), substantially lower than general population thresholds. Conclusion This study identifies an accentuated BMI-MS relationship in Chinese PLWHA, with metabolic complications emerging at atypically low BMI values. The proposed BMI threshold of 20 kg/m² for MS risk stratification—25% below standard obesity criteria. Urgent adoption of HIV-specific metabolic screening is needed, prioritizing early BMI-guided interventions to reduce cardiovascular risks, even in non-obese individuals.
- 1 April 2025
- Published by Springer Nature in Research Square
Open AccessThe Unique Relationship between Body Mass Index and Metabolic Syndrome in AIDS Patients
Introduction Metabolic syndrome (MS) poses substantial health risks for people living with HIV/AIDS (PLWHA). While body mass index (BMI) is a well-established predictor of MS in the general population, its association with MS in PLWHA remains poorly characterized, particularly in China. This study investigates the relationship between BMI and MS in Chinese AIDS patients, with emphasis on population-specific metabolic risk patterns andthreshold deviations from general population benchmarks. Methods We enrolled 482 hospitalized AIDS patients stratified by BMI categories: underweight (<18.5 kg/m², n=92), normal weight (18.5–23.9 kg/m², n=311), and overweight/obese (≥24 kg/m², n=79). MS diagnosis followed Chinese Diabetes Society (CDS) criteria. Comparative analyses of blood pressure, fasting glucose, and lipid profiles were conducted across groups. Statistical approaches included Spearman correlation for BMI-MS associations, multivariate logistic regression (adjusted for age, sex, and metabolic parameters), and ROC curve analysis to determine BMI thresholds predictive of MS. Results The overall MS prevalence was 8.92% (43/482), with striking disparities between groups: overweight/obese patients demonstrated 3.5-fold higher MS prevalence than normal-weight counterparts (24.1% vs. 6.8%, P<0.001). Metabolic derangements were disproportionately elevated in the overweight/obese group, including hypertension (31.6% vs. 12.2%) and hypertriglyceridemia (44.3% vs. 21.5%, both P<0.05). BMI showed strong positive correlations with MS diagnosis (r=0.42, P<0.001) and MS component burden (r=0.38, P<0.001). Multivariate analysis identified BMI as an independent MS predictor (adjusted OR=1.15 per unit increase, 95% CI:1.06–1.25, P<0.05). ROC analysis revealed a clinically relevant BMI cut-off of 20 kg/m² for MS prediction (AUC=0.79), substantially lower than general population thresholds. Conclusion This study identifies an accentuated BMI-MS relationship in Chinese PLWHA, with metabolic complications emerging at atypically low BMI values. The proposed BMI threshold of 20 kg/m² for MS risk stratification—25% below standard obesity criteria. Urgent adoption of HIV-specific metabolic screening is needed, prioritizing early BMI-guided interventions to reduce cardiovascular risks, even in non-obese individuals.
- 19 July 2016
- Published by Springer Nature in Diabetology International
- Vol. 8 (1) , 14-22
Metabolic disturbances: role of the circadian timing system and sleep
The incidence of metabolic disorders such as obesity and diabetes is on the rise, and food quality is not alone to blame. Sleep disturbances, altered feeding time and circadian disruption are linked to metabolic disturbances in many clinical research studies and cross-sectional analyses. This review tried to summarize the role of the circadian timing system and sleep on energy and metabolic homeostasis. We also tried to explain the molecular and endocrine mechanisms behind circadian misalignment and sleep disorders that lead to metabolic disorders.
- 19 July 2016
- Published by Springer Nature in Diabetology International
- Vol. 8 (1) , 14-22
Metabolic disturbances: role of the circadian timing system and sleep
The incidence of metabolic disorders such as obesity and diabetes is on the rise, and food quality is not alone to blame. Sleep disturbances, altered feeding time and circadian disruption are linked to metabolic disturbances in many clinical research studies and cross-sectional analyses. This review tried to summarize the role of the circadian timing system and sleep on energy and metabolic homeostasis. We also tried to explain the molecular and endocrine mechanisms behind circadian misalignment and sleep disorders that lead to metabolic disorders.
- 18 March 2011
- Published by Taylor & Francis in Molecular Physics
- Vol. 109 (6) , 831-838
The prominent enhancing effect and mechanism of the methyl group in the X···Y (X=O, S, H3CO, H3CS, (H3C)2O, (H3C)2S; Y=HCN, HNC) hydrogen-bonded complex
An ab initio computational study of the enhancing role of the methyl group in the M···H (M=S and O) hydrogen bond has been carried out at the QCISD/6-311++G(2df,2p) level. The bond lengths, frequency shifts, and interaction energies were analysed. The methyl group of the electron donor plays a positive role in the formation of the hydrogen bond. Its enhancing role is stronger in the O···H hydrogen bond than in the S···H hydrogen bond. The results show that the methyl group has a prominent effect on the strength of the hydrogen bond. The interaction energy is increased by 347% for the Me2O–HCN complex relative to that for the O–HCN complex. The enhancing mechanism of the methyl group has been analysed by means of natural bond orbital (NBO) theory. The electrostatic interaction is of more importance to the O···H hydrogen bond, whereas dispersion and charge-transfer interactions play a more significant role in the S···H hydrogen bond.
- 18 March 2011
- Published by Taylor & Francis in Molecular Physics
- Vol. 109 (6) , 831-838
The prominent enhancing effect and mechanism of the methyl group in the X···Y (X=O, S, H3CO, H3CS, (H3C)2O, (H3C)2S; Y=HCN, HNC) hydrogen-bonded complex
An ab initio computational study of the enhancing role of the methyl group in the M···H (M=S and O) hydrogen bond has been carried out at the QCISD/6-311++G(2df,2p) level. The bond lengths, frequency shifts, and interaction energies were analysed. The methyl group of the electron donor plays a positive role in the formation of the hydrogen bond. Its enhancing role is stronger in the O···H hydrogen bond than in the S···H hydrogen bond. The results show that the methyl group has a prominent effect on the strength of the hydrogen bond. The interaction energy is increased by 347% for the Me2O–HCN complex relative to that for the O–HCN complex. The enhancing mechanism of the methyl group has been analysed by means of natural bond orbital (NBO) theory. The electrostatic interaction is of more importance to the O···H hydrogen bond, whereas dispersion and charge-transfer interactions play a more significant role in the S···H hydrogen bond.